Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$1.53
$1.51
$1.05
$5.17
$165.67M0.31.33 million shs1.09 million shs
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$33.63
-0.4%
$28.00
$0.94
$79.02
$237.88M-6.0135,280 shs43,115 shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$3.65
+0.3%
$2.25
$0.73
$3.90
$230.38M0.7326,806 shs294,650 shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.00
$1.22
$8.45
$45.46M1.5329,344 shs42 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
0.00%-10.00%+5.52%+6.25%+14.18%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-0.41%-5.16%+20.06%+4.54%+2,799.14%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
+0.27%+25.43%+68.20%+162.59%+46.00%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%+4,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
2.0232 of 5 stars
3.61.00.00.01.91.70.6
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
1.6659 of 5 stars
3.62.00.00.00.02.50.0
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
2.5126 of 5 stars
3.51.00.00.03.43.30.0
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.11
Buy$8.71469.56% Upside
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
3.13
Buy$83.25147.55% Upside
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
3.00
Buy$6.0064.38% Upside
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NBRV, DRUG, ACRS, and GALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$6.00
7/2/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
6/25/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/23/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
6/17/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
5/28/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$8.00
5/21/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/14/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $16.00
5/13/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/13/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$18.72M8.85N/AN/A$1.44 per share1.06
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/A$0.92 per shareN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.68) per shareN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$35.59M0.00N/AN/A$0.10 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$2.06M-$0.36N/AN/AN/AN/A-14.56%-14.29%8/13/2025 (Estimated)
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/A

Latest NBRV, DRUG, ACRS, and GALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025N/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$0.59N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.16N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.14N/AN/AN/A$1.34 millionN/A
5/15/2025Q2 2025
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$0.39-$0.29+$0.10-$0.29N/AN/A
5/15/2025Q1 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.20-$0.15+$0.05-$0.15N/AN/A
5/6/2025Q1 2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
5.06
5.06
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A
126.01
126.01
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
0.08
0.08
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.12
0.85
0.52

Institutional Ownership

CompanyInstitutional Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
40.52%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
100108.28 million101.35 millionOptionable
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A7.04 million4.04 millionNot Optionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
963.29 million31.58 millionOptionable
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
7032.02 million31.49 millionNot Optionable

Recent News About These Companies

Nabriva Therapeutics plc (NBRVF)
Meitheal gains rights to Contempo
Meitheal gains rights to CONTEPO from Nabriva in North America
Nabriva Therapeutics PLC NBRVF
Nabriva Therapeutics files patent for a dosing regimen for fosfomycin treatment
NBRV - Nabriva Therapeutics plc
NBRV Nabriva Therapeutics plc
Nabriva Therapeutics Provides Corporate Update
Nabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosis
Nabriva's stock is up after sharing antibiotic news

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$1.53 0.00 (0.00%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.52 -0.01 (-0.65%)
As of 08/1/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Bright Minds Biosciences stock logo

Bright Minds Biosciences NASDAQ:DRUG

$33.63 -0.14 (-0.41%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$33.72 +0.09 (+0.28%)
As of 08/1/2025 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$3.65 +0.01 (+0.27%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.74 +0.09 (+2.44%)
As of 08/1/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Nabriva Therapeutics stock logo

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.